Quest Diagnostics INC Form 4 insider transactions

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, reports acquiring 60 shares of common stock through a dividend reinvestment plan and discloses total holdings.

Director Timothy M. Ring reports acquisition of phantom stock units and updates to beneficial ownership of Quest Diagnostics shares.

Mark A. Gardner, SVP of Molecular Gen & Oncol at Quest Diagnostics, disposed of 120 shares of common stock to cover tax withholding obligations.

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, exercised stock options and sold shares on August 29, 2024.

Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, reported selling 1,990 shares of common stock at an average price of $153.2612 on August 28, 2024.

Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, reported the disposition of 74 shares of common stock to cover tax withholding obligations from vesting restricted share units on August 14, 2024.

Mark Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports the acquisition and disposal of company stock.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports the acquisition of 21 shares of common stock through a dividend reinvestment plan.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reports the acquisition and disposal of company stock, including dividend reinvestments and transactions within the company's stock purchase and 401(k) plans.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, reports acquiring and disposing of common stock.

Vicky B. Gregg, a director at Quest Diagnostics, acquired 77 shares of common stock through a dividend reinvestment plan at a price of $146.973 per share.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, disposed of 3,910 shares of common stock to cover tax withholding obligations arising from the vesting of restricted share units.

Director Timothy M. Ring reports acquisition of phantom stock units and updates to direct ownership of Quest Diagnostics shares due to dividend reinvestment.

Robert B. Carter, a director at Quest Diagnostics, acquired 1,482 shares of common stock through a restricted stock unit award on May 16, 2024.

Director Gary M. Pfeiffer reports acquiring 1,482 shares of Quest Diagnostics common stock through restricted share units and disposing of an unspecified amount.

Director Timothy M. Ring reports acquisition of 1,482 restricted share units and updates beneficial ownership in Quest Diagnostics.

Director Timothy L. Main reported acquiring 1,482 restricted share units of Quest Diagnostics on May 16, 2024.

Vicky B. Gregg, a director at Quest Diagnostics, acquired 1,482 restricted share units on May 16, 2024.

Director Wright L. Lassiter III reports the acquisition of restricted share units and shares via dividend reinvestment in Quest Diagnostics.

Director Denise M. Morrison reports acquisition of restricted share units and disposal of common stock through dividend reinvestment.

Tracey Doi, a director at Quest Diagnostics, acquired 1,482 restricted share units on May 16, 2024.

Luis Diaz, a director at Quest Diagnostics, acquired 1,482 restricted share units on May 16, 2024.

Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, reported the sale of 1,760 shares of common stock at $140 per share on April 29, 2024, according to a Form 4 filing.

Vicky B. Gregg, a director at Quest Diagnostics, increased her holdings through a dividend reinvestment plan.

Karthik Kuppusamy, SVP at Quest Diagnostics, reports acquisition and disposal of company stock, including dividend reinvestment and transactions within the company's stock purchase and 401(k) plans.

Patrick Plewman, SVP at Quest Diagnostics, reports acquiring 69 shares of common stock through a dividend reinvestment plan and stock purchase plan.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquisition of common stock and restricted share units.

Director Timothy M. Ring reports acquisition of phantom stock units and adjustments to holdings due to dividend reinvestment.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, disposed of 170 shares of common stock to cover tax withholding obligations arising from the vesting of restricted share units on March 26, 2024.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, disposed of shares to cover tax withholding obligations arising from the vesting of restricted share units.